Kazakhstan Pharmaceuticals and Healthcare Report Q2 2008

Publication Date	April 2008
Publisher	Business Monitor
Product Type	Report
Pages	56
ISBN Number	not applicable
Product Code	BMI01647

Price

£425.00
approximately: $835 | €540

PDF immediate delivery

Order above formats by FAX

Summary

The key driver for the expansion of the pharmaceutical market in Kazakhstan is the underlying economic development and higher sales of oil. As BMI expects the economy to grow by around 8% in 2008, the benefits should be translated in an increase in both healthcare and pharmaceutical expenditure. As part of its healthcare system modernisation programme, the government is planning to raise the amount of GDP spent on healthcare to 4% in 2008. By 2012, BMI expects the market to be worth around US$1.14bn, growing at an annual rate in excess of 12%.Work on 56 hospitals and 83 outpatient hospitals scheduled for 2008 will support this development.

However, in the BMI's revised Business Environment Ranking matrix for Central and Eastern Europe (CEE) for Q208, Kazakhstan is ranked 15th of the 16 regional markets surveyed. The country is placed only above Serbia, down one place from the previous quarter, when it shared the 14th spot with Ukraine.

While enjoying a considerable level of political and economic stability, the country is marked down for absolute market value and per capita consumption of medicines, as well as the lack of universal reimbursement. More recently, the government revealed plans to introduce a fixed average price for outpatient medicines, which would be reflected negatively in market value and pharmaceutical companies' revenues.

Nevertheless, the market will remain reliant on imports. Leading foreign players include French Sanofi- Aventis (France), Hungary's Gedeon Richter, Swiss Nycomed and Berlin Chemie-Menarini.

Chimpharm is the main domestic producer of pharmaceuticals, accounting for over half of total local output. In recent years, Asian generic companies (including Indian and Malaysian producers) have made more of an impact on the Kazakhstan's pharmaceutical marketplace, although this has also led to a rise in counterfeit products.

In terms of other medical industries in Kazakhstan, the production of medical devices is relatively limited, accounting for under 10% of the market. Key barriers to market access for foreign producers include costly registration, the need for a Certificate of Conformance, tax levied on some medical devices and the lack of transparency in public-sector procurement. On the other hand, healthcare system modernisation, work on telemedicine and mobile medicine in rural regions and the government's desire to increase the role of the private sector will provide promising commercial opportunities for imports, which are mostly sourced from Germany, Russia, the US and Japan.

Content

Executive Summary
Kazakhstan Pharmaceuticals And Healthcare SWOT
Kazakhstan Political SWOT
Kazakhstan Economic SWOT
Kazakhstan - Business Environment Ranking
- Table: CEE Pharmaceutical Business Environment Ratings
Limits Of Potential Returns
Risks To Realisation Of Returns
Kazakhstan - Market Summary
Regulatory Regime
Intellectual Property Environment
Counterfeit Drugs
Pricing and Reimbursement Regime
- Table: Price Components And Add-ons For Imported And Locally Produced Generic Medicines (KZT)
Recent Pricing And Reimbursement Developments
- Table Top 10 Manufacturers By Value Of Hospital Purch
- Table Top 10 INNs By Value Of Hospital Purchases
Industry Developments
Epidemiology
Healthcare Sector
Healthcare Sector Financing
- Table: Top 10 ATC Groups By Value Of Hospital Purchas
- Table: Top 10 ATC Groups By Retail Pharmacy Sales
Domestic Pharmaceutical Industry
Wholesale And Retail
Recent Domestic Industry Developments
Foreign Pharmaceutical Industry
- Table: Indo-Kazakh Trade Figures (US$mn)
Recent Foreign Industry Developments
- Table: Pharmaniaga Key Products
Medical Devices
- Table Medical Devices Market In Kazakhstan (US$mn)
Industry Forecast Sce28
Overall Market Forecast
- Table: Kazakhstan - Drug Expenditure And Prescription Market Indicators
Key Growth Factors - Industry
- Table: Kazakhstan Health Expenditure Forecast Indicators
Key Growth Factors - Macroeconomic
- Table: Economic Activity
Patented Market Forecast
- Table: Kazakhstan's Patented Drug Market Indicators (US$'000 unless otherwise stated)
Generics Market Forecast
- Table: Kazakhstan's Generics Market Forecast Indicators
OTC Market Forecast
- Table: Kazakhstan OTC Market Forecast Indicators (US$'000 unless otherwise stated)
Export/Import Market Forecasts
- Table: Trade Figures (US$mn)
- Table Retail Sales Structure Of Imports By Pharmaceutical Subgroups, 2006
- Table: Top 15 Distributors By Value Importing Pharmaceuticals Into Kazakhstan, 2006
- Table: Top 15 Distributors By Volume Importing Pharmaceuticals Into Kazakhstan, 2006
Other Healthcare Data Forecasts
- Table: Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Competitive Landscape
- Table: Top 10 Manufacturers By Value Of Hospital Purchases
- Table: Top 10 Manufacturers By Retail Pharmacy Sales
- Table: Top 10 Trade Names By Value Of Hospital Purcha
- Table: Top 10 INNs By Value Of Hospital Purchases
- Table: Top 10 INNs by Retail Pharmacy Sales
Company Monitor
Foreign Companies
Nycomed
Ranbaxy
Indigenous Companies
Chimpharm
Romat FK
BMI Forecast Modelling
How We Generate Our Industry Forecasts
Pharmaceutical Industry
Sources
Business Environment Ranking Pharmaceutical Ratings: Revised Methodology
Ratings Overview
- Table: Pharmaceutical Business Environment Indicators